Credit Suisse upgrades Biogen Idec (Nasdaq: BIIB) from Underperform to Neutral. Price target $60.

The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE